| scholarly article | Q13442814 |
| P2093 | author name string | Mathew W Moore | |
| Philip D Cotter | |||
| Deepti Babu | |||
| P2860 | cites work | Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma | Q39401378 |
| Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions | Q44735365 | ||
| Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics | Q46661181 | ||
| HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. | Q54551877 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. | Q27851590 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| HER2 testing in gastric cancer: a practical approach | Q28256814 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time | Q35033300 | ||
| The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers | Q35832370 | ||
| Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. | Q36136786 | ||
| The role of companion diagnostics in the development and use of mutation-targeted cancer therapies | Q36561648 | ||
| Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders | Q37144244 | ||
| Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel | Q37773748 | ||
| A challenging drug development process in the era of personalized medicine | Q37938430 | ||
| Challenges in the development of companion diagnostics for neuropsychiatric disorders | Q37948846 | ||
| Using pharmacogenetics in real time to guide warfarin initiation: a clinician update | Q37965130 | ||
| Current management and novel agents for malignant melanoma | Q37983934 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 485-496 | |
| P577 | publication date | 2012-07-01 | |
| P1433 | published in | Personalized Medicine | Q19946312 |
| P1476 | title | Challenges in the codevelopment of companion diagnostics. | |
| P478 | volume | 9 |
| Q44289303 | Considerations for the successful co-development of targeted cancer therapies and companion diagnostics |
| Q26863622 | Murine models of inflammatory bowel disease (IBD): challenges of modeling human disease |
| Q91826167 | Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery |
Search more.